Clinical and anamnestic analysis of patients with Stevens–Johnson syndrome/toxic epidermal necrolysis hospitalised in Moscow. Development of a prognostic model of unfavourable outcomes



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Stevens–Johnson syndrome and toxic epidermal necrolysis are severe life-threatening conditions characterized by massive lesions of the skin and mucosa. At present, considering the high mortality rate, one of the most promising areas of research is the study of predictors of the severity of the pathology, since prognosis of the disease can further influence the choice of treatment strategy.

AIM: Determination of epidemiological features, identification of clinical and laboratory predictors of the disease severity, and construction of a prognostic model for patients with Stevens–Johnson syndrome and toxic epidermal necrolysis within the framework of analysis of electronic medical records of Moscow.

MATERIALS AND METHODS: The study was based on a retrospective analysis of medical records of patients with SJS/TEN from 2020 to 2023. Initially, 230 individuals over 18 years of age were included in the analysis. As a result of selection from the primary cohort, 122 patients satisfying the criteria for the diagnosis of Stevens–Johnson syndrome and toxic epidermal necrolysis were included in the final analysis. Patients did not undergo additional follow-up as part of this study.

RESULTS: In the analyzed cohort, a prevalence of female patients (n = 72; 59.01 %) over male patients (n = 50; 40.99 %) was observed. Lethal outcome was recorded in 27 (22.13 %) patients, of which 21 (77.8 %) had a verified diagnosis of toxic epidermal necrolysis, which was associated with a higher incidence of death compared to Stevens–Johnson syndrome (n = 6 (p = 0.001)). It was found that 112 (91.8 %) cases were likely associated with medication use, while 10 (8.2 %) presented a verified infectious agent Mycoplasma pneumoniae. Antiepileptic drugs were the most frequent cause of drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis (n = 62; 55.4 %). Based on the analysed clinical and laboratory data, a prognostic model was developed to determine the probability of lethal outcome, including decreased serum bicarbonate, increased levels of c-reactive protein, fibrinogen, fever, hypoalbuminemia.

CONCLUSION: Stevens–Johnson syndrome and toxic epidermal necrolysis are rare conditions with a high mortality rate and high risk of disabling complications. Early verification of the diagnosis and stratification of patients by severity group is optimal for the choice of treatment tactics; however, further work is currently required to standardise the assessment of the severity of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Full Text

Restricted Access

About the authors

Ekaterina A. Nikitina

Moscow City Hospital 52; The First Sechenov Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: katrin88866@gmail.com
ORCID iD: 0000-0002-0865-8355
SPIN-code: 3507-9106
Россия, Moscow; Moscow

Alexander D. Dushkin

Moscow City Hospital 52; National Medical Research Center for High Medical Technologies — Central Military Clinical Hospital named after A.A. Vishnevsky; S.M. Kirov Military Medical Academy

Email: alex@drdushkin.ru
ORCID iD: 0000-0002-8013-5276
SPIN-code: 3857-0010
Россия, Moscow; Moscow; Moscow

Yuriy V. Streltsov

Moscow City Hospital 52

Email: strelok790@mail.ru
ORCID iD: 0009-0009-1822-8533
SPIN-code: 8899-9425
Россия, Moscow

Sergey S. Andreev

Moscow City Hospital 52

Email: nerowolf@mail.ru
ORCID iD: 0000-0002-9147-4636
SPIN-code: 4372-7358
Россия, Moscow

Tatyana S. Kruglova

Moscow City Hospital 52

Email: surckova.t@yandex.ru
ORCID iD: 0000-0002-4949-9178
SPIN-code: 2884-5000
Россия, Moscow

Ulyana A. Markina

Moscow City Hospital 52

Email: itchermd@gmail.com
ORCID iD: 0000-0002-6646-4233
SPIN-code: 6424-0012
Россия, Moscow

Marina S. Lebedkina

Moscow City Hospital 52

Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
SPIN-code: 1857-8154
Россия, Moscow

Maryana A. Lysenko

Moscow City Hospital 52; The Russian National Research Medical University named after N.I. Pirogov

Email: lysenkiMA@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
SPIN-code: 3887-6250

MD, Dr. Sci. (Medicine), Professor

Россия, Moscow; Moscow

Darya S. Fomina

Moscow City Hospital 52; The First Sechenov Moscow State Medical University (Sechenov University); Astana Medical University

Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538

MD, Cand. Sci. (Medicine), Assistant Professor

Россия, Moscow; Moscow; Republic of Kazakhstan, Astana

References

  1. Fukasawa T, Takahashi H, Kameyama N, et al. Development of an electronic medical record-based algorithm to identify patients with Stevens–Johnson syndrome and toxic epidermal necrolysis in Japan. PLoS One. 2019;14(8):e0221130. doi: 10.1371/journal.pone.0221130
  2. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996–2011. doi: 10.1016/S0140-6736(16)30378-6 EDN: YDEHZJ Erratum in: Lancet. 2017;390(10106):1948. doi: 10.1016/S0140-6736(17)31656-2
  3. Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–1247. doi: 10.1016/j.jid.2017.01.031
  4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–1397. doi: 10.1016/j.jid.2016.03.023
  5. Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625–645. doi: 10.1111/ddg.12747
  6. Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157–162. doi: 10.1001/archdermatol.2009.540
  7. Crowder CA, Jeney SES, Kraus CN, et al. Vulvovaginal involvement in Stevens–Johnson syndrome and toxic epidermal necrolysis: management and techniques used to reduce gynecologic sequelae. Int J Dermatol. 2022;61(2):158–163. doi: 10.1111/ijd.15676 EDN: NOHFGB
  8. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153. doi: 10.1046/j.1523-1747.2000.00061.x
  9. Hu CH, Chang NJ, Liu EK, et al. SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. J Eur Acad Dermatol Venereol. 2013;27(5):628–633. doi: 10.1111/j.1468-3083.2012.04502.x
  10. Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens–Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138(11):2315–2321. doi: 10.1016/j.jid.2018.04.027 Erratum in: J Invest Dermatol. 2019;139(2):495–496. doi: 10.1016/j.jid.2018.11.013
  11. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237–245. doi: 10.1097/BCR.0b013e31820aafbc
  12. Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens–Johnson syndrome/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155(4): 448–454. doi: 10.1001/jamadermatol.2018.5605
  13. Torres-Navarro I, Briz-Redón Á, Botella-Casas G, et al. Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens–Johnson syndrome/toxic epidermal necrolysis. J Dermatol. 2020;47(10):1182–1186. doi: 10.1111/1346-8138.15490 EDN: VWARHN
  14. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–68. doi: 10.1038/clpt.2009.252
  15. Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients – treatment and outcome. Allergol Int. 2016;65(1):74–81. doi: 10.1016/j.alit.2015.09.001
  16. Wasuwanich P, So JM, Chakrala TS, et al. Epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023;13:17–25. doi: 10.1016/j.jdin.2023.06.014 EDN: GIKANS
  17. Cheung CMT, Chang MM, Li JJX, Chan AWS. Stevens–Johnson syndrome and toxic epidermal necrolysis in Hong Kong. Hong Kong Med J. 2024;30(2):102–109. doi: 10.12809/hkmj2210131
  18. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–1165. doi: 10.1001/archderm.123.9.1160
  19. White KD, Abe R, Ardern-Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6(1):38–69. doi: 10.1016/j.jaip.2017.11.023 EDN: YFCDNB
  20. Marks ME, Botta RK, Abe R, et al. Updates in SJS/TEN: collaboration, innovation, and community. Front Med. 2023;10:1213889. doi: 10.3389/fmed.2023.1213889 EDN: KJGZMX
  21. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56(4):419–425. doi: 10.2332/allergolint.O-07-483
  22. Charlton OA, Harris V, Phan K, et al. Toxic epidermal necrolysis and Steven–Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020;9(7):426–439. doi: 10.1089/wound.2019.0977 EDN: RGWKZX
  23. Mani R, Monteleone C, Schalock PC, et al. Rashes and other hypersensitivity reactions associated with antiepileptic drugs: a review of current literature. Seizure. 2019;71:270–278. doi: 10.1016/j.seizure.2019.07.01 EDN: DPEUQP
  24. Sibbald C, Putterman E, Micheletti R, et al. Retrospective review of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol. 2020;37(3):461–466. doi: 10.1111/pde.14118 EDN: ISYIYF
  25. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272–276. doi: 10.1038/sj.jid.5700068
  26. Dobry AS, Himed S, Waters M, Kaffenberger BH. Scoring assessments in Stevens–Johnson syndrome and toxic epidermal necrolysis. Front Med. 2022;9:883121. doi: 10.3389/fmed.2022.883121 EDN: DJYLYV
  27. Nizamoglu M, Ward JA, Frew Q, et al. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: a regional burns centre experience. Burns. 2018;44(3):603–611. doi: 10.1016/j.burns.2017.09.015
  28. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000 Faculty Rev–612. doi: 10.12688/f1000research.24748.1 EDN: KKOUAN

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Curves ROC (a) and PR (b) in cross-validation samples.

Download (399KB)
3. Fig. 2. Cross-tabulation matrix for SCORTEN (a) and regressive model (b)

Download (435KB)

Copyright © ABV-press,



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies